Edition:
United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

20.51USD
20 May 2019
Change (% chg)

-- (--)
Prev Close
$20.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
175,819
52-wk High
$56.75
52-wk Low
$14.13

Billet, Isabelle 

Ms. Isabelle Billet serves as Chief Strategy and Business Development Officer of the company. From July 2013 until joining the Company as Chief Strategy and Business Development Officer, Ms. Billet worked for IBHC Advisors LLC, a consulting firm she founded which assisted medical device companies in their organic and inorganic growth strategies and supported Private Equity firms on their investment strategy and due diligence. From 2010 to 2013, Ms. Billet worked at Cardinal Health, Inc where she served as Senior Vice President of Marketing and Innovation for the Medical segment focusing on their private brand portfolio development. From 2005 to 2010, she was Vice President Marketing and New Business Development for C.R. Bard Medical division. She worked for Johnson and Johnson from 1992 to 2005, splitting her tenure between Advanced Sterilization Products and Ethicon, Inc in positions of increasing responsibilities in marketing and new business development in France, Europe and US. Ms. Billet spent the first 7 years of her career as the head pharmacist and material manager for a private hospital in France. Ms. Billet is a member of the Clinical Innovations Board of Directors, a medical device company exclusively focused in Labor and Delivery and Neonates Intensive Care. She has an MBA from EM Lyon Business School, France and Cranfield School of Management, UK and a Doctorate in Pharmacy from Montpellier University in France. Ms. Billet since 2016 has provided consulting services to the Company through her consulting firm IBHC Advisors LLC. She was paid $171,094 in 2017 and $220,645 in 2018 through the date of this filing for her services.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --